Celularity (CELU) Share-based Compensation (2020 - 2025)
Celularity (CELU) posted quarterly Share-based Compensation of $9.6 million for Q4 2025, up 217.04% year-over-year from $3.0 million in Q4 2024, and up 1936.09% quarter-over-quarter from $471000.0 in Q3 2025.
Celularity (CELU) Share-based Compensation (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Share-based Compensation for 6 consecutive years, with $9.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 217.04% year-over-year to $9.6 million; the TTM figure through Dec 2025 stood at $12.8 million (up 2850.69% YoY), while the FY2025 annual figure was $10.4 million, up 2291.24% from the prior year.
- Share-based Compensation grew to $9.6 million in Q4 2025 per CELU's latest filing, from $471000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $28.2 million in Q2 2021 and bottomed at -$32.7 million in Q4 2021.
- Historically, Share-based Compensation has averaged $800421.1 across 5 years, with a median of $2.4 million in 2022.
- Annual changes were most pronounced in 2021 — Share-based Compensation plunged 3322.83% — and 2025, when it surged 638.66%.
- Celularity's Share-based Compensation stood at -$32.7 million in 2021, then soared by 65.37% to -$11.3 million in 2022, then dropped by 0.03% to -$11.3 million in 2023, then rose by 27.75% to -$8.2 million in 2024, then soared by 217.04% to $9.6 million in 2025.
- Business Quant data shows CELU's Share-based Compensation at $9.6 million in Q4 2025, $471000.0 in Q3 2025, and $108000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.59 Mn |
| Dec 31, 2025 | 9.59 Mn |
| Sep 30, 2025 | 471,000.00 |
| Sep 30, 2025 | 471,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 108,000.00 |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | -8.19 Mn |
| Dec 31, 2024 | -8.19 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 5.60 Mn |
| Mar 31, 2024 | 357,000.00 |
| Mar 31, 2024 | 357,000.00 |
| Dec 31, 2023 | -11.34 Mn |
| Dec 31, 2023 | -11.34 Mn |
| Jun 30, 2023 | 7.79 Mn |
| Jun 30, 2023 | 7.79 Mn |